aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Artiva Biotherapeutics, founded with a mission to advance cancer treatment, focuses on developing allogeneic natural killer (NK) cell therapies and chimeric antigen receptor NK (CAR-NK) therapies. The company aims to provide innovative solutions for both blood cancers and solid tumors. By leveraging cutting-edge biotechnology, Artiva seeks to offer effective and scalable immunotherapy options that can be readily available to patients in need.
Notable figures affiliated with Artiva include Neha Krishnamohan, who serves as CFO and EVP of Corporate Development, and Jennifer Bush, the Chief Operating Officer. The company has achieved significant milestones, such as dosing the first patient in a Phase trial of their AlloNK® cell therapy candidate for lupus nephritis. Artiva's advancements in NK cell therapies have positioned it as a key player in the biotech industry, contributing to the broader impact on cancer treatment and immunotherapy.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Biotech
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Artiva Biotherapeutics founded?
Artiva Biotherapeutics was founded in 2019.
Where is Artiva Biotherapeutics's headquarters located?
Artiva Biotherapeutics's headquarters is located in San Diego, CA, US.
When was Artiva Biotherapeutics's last funding round?
Artiva Biotherapeutics's most recent funding round was for $120M (USD) in February 2021.
How many employees does Artiva Biotherapeutics have?
Artiva Biotherapeutics has 78 employees as of Feb 5, 2024.
How much has Artiva Biotherapeutics raised to-date?
As of July 05, 2023, Artiva Biotherapeutics has raised a total of $198M (USD) since Feb 26, 2021.
Add Comparison
Total Raised to Date
$198M
USD
Last Update Feb 26, 2021
Last Deal Details
$120M
USD
Feb 26, 2021
Series B
Total Employees Over Time
78
As of Feb 2024
Artiva Biotherapeutics Address
4747 Executive Drive
Suite 1150
San Diego,
California
92121
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts